July 26, 2024
Take a chill pill
There is no way to sugarcoat the 2nd quarter earnings from Dexcom – a missed number and lowered guidance is never a good thing. The company frankly acknowledged they did not execute taking ownership of their misstep. This admission and frankness didn’t help much as investors quickly reacted – I would say overreacted to the news sending Dexcom shares down over 40% in pre-market trading.
Now let’s get a few things straight before everyone starts panicking –
1. This miss has NOTHING whatsoever to do with Ozempic.
2. The CGM market is as a strong as ever . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
